Zanubrutinib in Japanese treatment-naive and relapsed/refractory patients with Waldenström macroglobulinemia and CLL/SLL

被引：0

作者：

Izutsu, Koji ^{[1
]}

Ishikawa, Takayuki ^{[2
]}

Shimada, Kazuyuki ^{[3
]}

Kubo, Kohmei ^{[4
]}

Kondo, Takeshi ^{[5
]}

Fujimoto, Katsuya ^{[6
]}

Fujisaki, Tomoaki ^{[7
]}

Kurahashi, Shingo ^{[8
]}

Nagafuji, Koji ^{[9
]}

Sakai, Rika ^{[10
]}

Jo, Tatsuro ^{[11
]}

Nakazato, Tomonori ^{[12
]}

Sunami, Kazutaka ^{[13
]}

Kasahara, Senji ^{[14
]}

Cohen, Aileen ^{[15
]}

Takai, Motohisa ^{[15
]}

Zhong, Jinhua ^{[16
]}

Takeuchi, Masahiro ^{[17
]}

机构：

[1] Natl Canc Ctr, 5-1-1 TsukijiChuo Ku, Tokyo, Japan

[2] Kobe City Med Ctr Gen Hosp, Kobe, Japan

[3] Nagoya Univ Hosp, Nagoya, Japan

[4] Aomori Prefectural Cent Hosp, Aomori, Japan

[5] Aiiku Hosp, Sapporo, Japan

[6] NHO Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan

[7] Matsuyama Red Cross Hosp, Matsuyama, Ehime, Japan

[8] Toyohashi Municipal Hosp, Toyohashi, Japan

[9] Kurume Univ Hosp, Kurume, Fukuoka, Japan

[10] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan

[11] Japanese Red Cross Nagasaki Genbaku Hosp, Nagasaki, Japan

[12] Yokohama Municipal Citizens Hosp, Yokohama, Kanagawa, Japan

[13] Okayama Med Ctr, Natl Hosp Org, Okayama, Japan

[14] Gifu Municipal Hosp, Gifu, Japan

[15] BeiGene USA Inc, San Mateo, CA USA

[16] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China

[17] Chiba Ken Canc Ctr, Chiba, Japan

来源：

INTERNATIONAL JOURNAL OF HEMATOLOGY | 2025年 / 121卷 / 04期

关键词：

Waldenstr & ouml; m Macroglobulinemia; Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Zanubrutinib; Bruton tyrosine kinase; Japanese; CHRONIC LYMPHOCYTIC-LEUKEMIA; RESPONSE ASSESSMENT; IBRUTINIB; LYMPHOMA; BTK;

D O I：

10.1007/s12185-025-03925-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Zanubrutinib is a selective second-generation Bruton tyrosine kinase inhibitor approved in various B-cell malignancies globally. The phase 1/2 BGB-3111-111 study evaluated the efficacy and safety of zanubrutinib 160 mg twice daily orally in Japanese patients with treatment-naive or relapsed/refractory mature B-cell malignancies. Here, efficacy results from Part 2 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL; n = 19) and Waldenstr & ouml;m macroglobulinemia (WM; n = 19), and safety results from Parts 1 (N = 6) and 2 (N = 49) are presented, with the first dose between 30 January, 2020, and 31 October, 2022. As of 10 May, 2023, investigator-assessed overall response rates were 100% (19/19) and 94.7% (18/19) in CLL/SLL and WM, respectively, with median follow-up of 27.9 and 26.8 months; 24-month progression-free survival rates were 71.4% and 100% in treatment-naive and relapsed/refractory CLL/SLL and 83.9% and 100% in treatment-naive and relapsed/refractory WM, respectively. In patients with B-cell malignancies, any-grade treatment-emergent adverse events (TEAEs) occurred in 53 (96.4%) and serious TEAEs in 18 (32.7%). Common TEAEs were platelet count decreased (18.2%), pyrexia (18.2%), COVID-19 (14.5%), and neutrophil count decreased (12.7%). With median follow-up > 2 years, zanubrutinib demonstrated durable efficacy in Japanese patients with CLL/SLL or WM and a favorable safety profile consistent with global phase 3 studies.

引用

页码：483 / 493

页数：11

共 23 条

[21] Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial [J].

Tam, Constantine S. ;

Brown, Jennifer R. ;

Kahl, Brad S. ;

Ghia, Paolo ;

Giannopoulos, Krzysztof ;

Jurczak, Wojciech ;

Simkovic, Martin ;

Shadman, Mazyar ;

Osterborg, Anders ;

Laurenti, Luca ;

Walker, Patricia ;

Opat, Stephen ;

Chan, Henry ;

Ciepluch, Hanna ;

Greil, Richard ;

Tani, Monica ;

Trneny, Marek ;

Brander, Danielle M. ;

Flinn, Ian W. ;

Grosicki, Sebastian ;

Verner, Emma ;

Tedeschi, Alessandra ;

Li, Jianyong ;

Tian, Tian ;

Zhou, Lei ;

Marimpietri, Carol ;

Paik, Jason C. ;

Cohen, Aileen ;

Huang, Jane ;

Robak, Tadeusz ;

Hillmen, Peter .

LANCET ONCOLOGY, 2022, 23 (08) :1031-1043

[22]

Tomlinson R, 2017, AUST FAM PHYSICIAN, V46, P493

[23] Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies [J].

Wiestner, Adrian .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) :128-130

← 1 2 3 →